Wang, Victoria E <br/><br/>
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.  [electronic resource] 

 -  Journal for immunotherapy of cancer  09 2017 
 - 75 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2051-1426 
<br/><br/><label>Standard No.: </label>10.1186/s40425-017-0281-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>B7-H1 Antigen--genetics<br/>Carcinoma, Neuroendocrine--drug therapy<br/>Gene Amplification<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Treatment Outcome<br/>Tumor Burden